Abstract Library

#1787 Towards Personalizing PRRT with [177Lu]-Dotatate to Minimise Renal Toxicity in Neuroendocrine Tumour Patients

Introduction: The kidney is a dose-limiting organ in [177Lu]-Dotatate PRRT (Lutate) and thus renal function is an important prescribing consideration for NET patients. The effect of baseline renal function on kidney absorbed dose is unclear.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Eslick E, Hayes A, Willowson K, Ryu H, Hennessy T,

Keywords: peptide receptor radionuclide therapy, Lutate, renal function, kidney absorbed dose,

#1156 Characterisation, Measurement and Biodistribution of an Improved Formulation of [Lu-177]-Octreotate

Introduction: Lu-177 can be made with high specific activity and no other isotopes of lutetium present, referred to as “no carrier added” (nca) Lu-177. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate (Auspep, Melb., AUS) with nca Lu-177 (“nca-LuTATE”) and used it in over 30 administrations in NETs patients.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Bailey D

Authors: Bailey D, Willowson K, Hennessy T, Schembri G, Snowdon G,

Keywords: lutetium, dosimetry, biodistribution, effective dose,